Drugs for male contraception

Bibliography

• COSENTINO MJ, MATLIN SA: Pharmacological developments in male contraception. Expert Opin. Invest. Drugs (1997) 6(6):635–653.
   PubMedGoogle Scholar
• ••A review with many useful references.
   Google Scholar
• BROOKS M: Men's views on male hormonal contraception-a survey of the views of attendees at a fitness centre in Bristol, UK. Br. J. Fam. Plann. (1998) 24(1):7–17.
   PubMedGoogle Scholar
• DE KRETSER DM, LOVELAND KL, MEINHARDT A, SIMORANGKIR D, WREFORD N: Spermatogenesis. Hum. Reprod. (1998) 13(Suppl.) :1–8.
   PubMedGoogle Scholar
• •A review of the fundamentals of spermatogenesis.
   Google Scholar
• Contraceptive Research and Development: Looking to the Future. Harrison PF, Rosenfield A (Eds.), National Academy Press, Washington, D.C., USA (1996).
   Google Scholar
• ••Assesses the needs of the field.
   Google Scholar
• Vasectomy: Permanent birth control for men. AVSC International, 79 Madison Ave., New York,NY 10016, USA (1995).
   Google Scholar
• RASPA RF: Complications of vasectomy. Am. Fam. Physician (1993) 48(7):1264–1268.
   PubMed Web of Science ®Google Scholar
• KRONMAL RA, KRIEGER JN, COXON V, WORTLEY P, THOMPSON L, SHERRARD DJ: Vasectomy is associated with an increased risk for urolithiasis. Am. J. Kidney Dis. (1997) 29 (2):207–213.
   PubMed Web of Science ®Google Scholar
• BRAUS P: Men who choose the sterile life. American Demographics (1995) December, pp.20. Intertec, Stamford, CT, USA.
   Google Scholar
• TRUSSELL J, LEVEQUE JA, KOENIG JD, et al.: The economic value of contraception: a comparison of 15 methods. Am. J. Public Health (1995) 85(4):494–503.
   PubMed Web of Science ®Google Scholar
• •An interesting analysis of contraception.
   Google Scholar
• The Birth Control Book: A Complete Guide to Your Contraceptive Options. Pasquale SA, Cadoff J (Eds.), Ballentine Books, London, UK (1996).
   Google Scholar
• BEHRE HM, KLIESCH S, PUEHSE G, REISSMANN T, NIESCHLAG E: High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men. J. Clin. Endocrinol. Metab. (1997) 82(5):1403–1408.
   PubMed Web of Science ®Google Scholar
• •Discusses this particular approach of contraception.
   Google Scholar
• SHETTY G, KRISHNAMURTHY H, KRISHNAMURTHY HN, BHATNAGAR AS, MOUDGAL NR: Effect of long-term treatment with aromatase inhibitor on testicular function of adult male bonnet monkeys (M-radiata). Steroids (1998) 63 (7-8):414–420.
   PubMed Web of Science ®Google Scholar
• ANDERSON RA, WALLACE EM, GROOME NP, BELLIS AJ, WU FCW: Physiological relationships between inhibin B, follicle stimulating hormone secretion and spermatogenesis in normal men and response to gonadotropin suppression by exogenous testosterone. Hum. Reprod. (1997) 12(4):746–751.
   PubMed Web of Science ®Google Scholar
• ZIRKIN BR: Spermatogenesis: its regulation by testosterone and FSH. Semin. Cell Dev. Biol. (1998) 9(4):417–21.
   PubMed Web of Science ®Google Scholar
• •A review which discusses this complex situation.
   Google Scholar
• TAPANAINEN JS, AITTOMAKI K, MIN J, VASKIVUO T, HUHTANIEMI IT: Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility. Nature Genet. (1997) 15(2):205–206.
   PubMed Web of Science ®Google Scholar
• MOUDGAL NR, MURTHY GS, KUMAR KMP, et al.: Responsiveness of human male volunteers to immunization with ovine follicle stimulating hormone vaccine: results of a pilot study. Hum. Reprod. (1997) 12(3):457–463.
   PubMed Web of Science ®Google Scholar
• BLANCO-RODRIGUEZ J: A matter of death and life: the significance of germ cell death during spermatogenesis. Int. J. Androl. (1998) 21 (5):236–248.
   PubMed Web of Science ®Google Scholar
• ROYERE D, GUERIF F, DE REVIERS MTR, PANTHIER S, LANSAC J: Apoptosis in male gonads. Contraception Fertilite Sexualite (1998) 26(7-8):517–521.
   Google Scholar
• D'ANIELLO A, DI FIORE MM, D'ANIELLO G, et al.: Secretion of d-aspartic acid by the rat testis and its role in endocrinology of the testis and spermatogenesis. FEBS Lett. (1998) 436 (1):23–27.
   PubMed Web of Science ®Google Scholar
• MAEDA T, SAKASHITA M, OHBA Y, NAKANISHI Y: Molecular cloning of the rat tpx-1 responsible for the interaction between spermatogenic and Sertoli cells. Biochem. Biophys. Res. Commun. (1998) 248(1):140–146.
   PubMed Web of Science ®Google Scholar
• MONSEES TK, GORNIG M, SCHILL WB, MISKA W: Possible involvement of proteases in the regulation of spermatogenesis. Andrologia (1998) 30(4-5):185–191.
   PubMed Web of Science ®Google Scholar
• SEPPALA M, KOISTINEN H, KOISTINEN R, et al.: Glycodelins: role in regulation of reproduction, potential for contraceptive development and diagnosis of male infertility. Hum. Reprod. (1998) 13 (Suppl.):262–269.
   PubMedGoogle Scholar
• HORST HJ, HOLTJE WJ, DENNIS M, COERT A, GEELEN J, VOIGT KD: Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Kiln. Wochenschr. (1976) 54(18)875–879.
   PubMedGoogle Scholar
• GUERIN JF, ROLLET J: Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int. J. Androl. (1988) 11 (3):187–199.
   PubMed Web of Science ®Google Scholar
• EDWARDS DA, HANES J, CAPONETTI Get al.: Large porous particles for pulmonary drug delivery. Science (1997) 276(5320):1868–1871.
   PubMed Web of Science ®Google Scholar
• •This paper discusses an interesting approach to delivery of drugs.
   Google Scholar
• MISRA A, PAL R, MAJUMDAR SS, TALWAR GP, SINGH O: Biphasic testosterone delivery profile observed with two different transdermal formulations. Pharm. Res. (1997) 14(9):1264–1268.
   PubMed Web of Science ®Google Scholar
• WILSON DE, MEIKLE AW, BOIKE SC, FAIRLESS AJ, ETHEREDGE RC, JORKASKY DK: Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men. J. Clin. Pharmacol. (1998) 38(1)54–59.
   Google Scholar
• MERIGGIOLA MC, BREMNER WJ, COSTANTINO A, DI CINTIO G, FLAMIGNI C: Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum. Reprod. (1998) 13(5):1225–1229.
   PubMed Web of Science ®Google Scholar
• •An interesting article which describes a particular approach to male contraception.
   Google Scholar
• SWERDLOFF RS, BAGATELL CJ, WANG C, et al.: Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J. Clin. Endocrinol. Metab. (1998) 83(10):3527–3533.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, WEINBAUER GF, NIESCHLAG E: Testosterone buciclate. Pharmacol. Biol. Clin. Appl. Androg. pp.471–479. Wiley-Liss, New York, NY, USA (1996).
   Google Scholar
• SUVISAARI J, SUNDARAM K, NOE G, et al.: Pharmacokinetics and pharmacodynamics of 7a-methyl-19-nortestosterone after intramuscular administration in healthy men. Hum. Reprod. (1997) 12(5):967–973.
   PubMed Web of Science ®Google Scholar
• COMBS DW: Male contraception. Ann. Reports Medicinal Chem. (1997) 32:191–200.
   Web of Science ®Google Scholar
• WAITES GMH, WANG C, GRIFFIN PD: Point of view review - Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility drug. Int. J. Androl. (1998) 21(2):8–12.
   PubMedGoogle Scholar
• YU ZH, CHAN HC: Gossypol as a male antifertility agent; why studies should have been continued. Int. J. Androl. (1998) 21(1):2–7.
   PubMed Web of Science ®Google Scholar
• FRICK J, JUNGWIRTH A, ROVAN E, KALLA N: A pill for the man Current status of fertility control in the man. Gynakol Geburtshilfliche Rundsch (1998) 38(1) :50–53.
   PubMed Web of Science ®Google Scholar
• LUE YH, HIKIM APS, WANG C, et al.: Triptolide: a potential male contraceptive. J. Androl. (1998) 19(4):479–486.
   PubMed Web of Science ®Google Scholar
• ZHEN QS, YE X, WEI ZJ: Recent progress in research on tripterygium: a male antifertility plant. Contraception (1995) 51 (2) :121–129.
   PubMed Web of Science ®Google Scholar
• HODEL C, SUTER K: Reversible inhibition of spermatogenesis with an indenopyridine (20–438). Arch. Toxicol. Suppl. 1 (1978) pp.323–326.
   Google Scholar
• COOK CE, WANI MC, JUMP JM, et al.: Structure-activity studies of 2,3,4,4a,5,9b-hexahydroindeno [1,2-c] pyridines as antispermatogenic agents for male contraception. J. Med. Chem. (1995) 38(5) :753–763.
   PubMed Web of Science ®Google Scholar
• •A medicinal chemistry approach to the development of male contraceptives.
   Google Scholar
• COOK CE, JUMP JM, ZHANG P, et al.: Exceptionally potent antispermatogenic compounds from 8-halogenation of (4aRS,5SR,9bRS)-hexahydroindeno [1,2-c] pyridines. J. Med. Chem. (1997) 40(14):2111–2112.
   PubMed Web of Science ®Google Scholar
• BJORDAHL JA, JOST LK, FAIL PA, COOK CE, EVENSON DP: Flow cytometric analysis of the antispermatogenic effects of an indenopyridine derivative. Biol. Reprod. (1997) 56(1):212. Abstract 518.
   Google Scholar
• HILD-PETITO S, REEL JR, LARNER JM, BLYE RP: Mechanism of action of a male antifertil-ity drug, CDB 4022 ([4aRS,5SR,9bRS]-2-ethy1-2,3,4,4a,5,9b-hexahydro-8-iodo-7-methy1-514-carbomethoxyphenyl]-1H-indeno(1,2-c)pyridine hydrochloride). Biol. Reprod. (1998) 58(Suppl.):169.
   Google Scholar
• HILD-PETITO S, MEISTRICH ML, REEL JR, BLYE RP: Protective effect of lupron depot on spermatogenesis and fertility in male rats treated orally with a potent indenopyridine (CDB 4022; [4aRS,5SR,9f3RS]-2-ethy1-7-methy1-2,3,4,4a,5,913-hexahydro-544-carbomethoxyphenyl]-1H-indeno[1,2-dpyridine-hydroiodide) {sic, The correct name is [4aRS,5SR,9bRS] -2-Ethy1-7-methy1-2,3,4,4a,5,9b-hexahydro-5-(4-carbomethoxyphenyl) -8--iodo-1H-indeno [1,2-c] pyridine (RTI-4587-073 or CDB 4022)1. XIVth Testis Workshop (1997) [Abstract].
   Google Scholar
• Zirkin, BR (Ed.), Springer-Verlag, New York (1998):202–213.
   Google Scholar
• ANAND RJK, KANWAR U, SANYAL SN: Calcium channel antagonist verapamil modulates human spermatozoal functions. Res. Exp. Med. (1994) 194(3) :165–178.
   PubMedGoogle Scholar
• BONFILS A, HUMBERT J, PHILIBERT D: RU 3117 a steroidal compound with high affinity for sigma sites in rat testis membranes. J. Steroid Biochem. Mol. Biol. (1996) 59 (1) 49–54.
   PubMed Web of Science ®Google Scholar
• WAGENFELD A, YEUNG CH, STRUPAT K, COOPER TG: Shedding of a rat epididymal sperm protein associated with infertility induced by ornidazole and alpha-chlorohydrin. Biol. Reprod. (1998) 58(5):1257–1265.
   PubMed Web of Science ®Google Scholar
• •This paper describes the mechanism of action of these potential contraceptives.
   Google Scholar
• WAGENFELD A, GROMOLL J, COOPER TG: Molecular cloning and expression of rat contraception associated protein 1 (cap 1), a protein putatively involved in fertilization. Biochem. Biophys. Res. Commun. (1998) 251(2):545–549.
   PubMed Web of Science ®Google Scholar
• BIALY G: Hormonal methods of male contraception are flawed and impractical. Pharmacol. Biol. Clin. Appl. Androg. pp.387–393. Wiley-Liss, New York, NY, USA (1996).
   Google Scholar
• •A good discussion of practical development needs.
   Google Scholar
• BANSODE FW, DWIVEDI AK, MAIKHURI JP, CHOWDHURY SR: Quantitative analysis of spermatogenesis in rats made azoospermic with compound CDRI 84/35. Contraception (1998) 58:175–182.
   Web of Science ®Google Scholar
• XU Y, TONG J, WANG Y, LIN N, QIAN S: Studies on the antifertility effect of bis-trichloromethyl sulfone and its reversibility in male rats. Yaoxue Xuebao (1998) 33(1):1-4. (Chem. Abstr. (1998) 129:129:255146.)
   Google Scholar
• BONN D: Male contraceptive research steps back into spotlight. Lancet (1999) 353:302.
   PubMed Web of Science ®Google Scholar